LY3473329
DrugAdministered orally.
NCT Number: NCT05778864
The main purpose of this study is to assess the amount of study drug (LY3473329) that reaches the bloodstream and the time it takes for the body to get rid of it when given to participants with renal (kidney) impairment compared to participants with normal renal function. The safety and tolerability of LY3473329 will also be evaluated in these participants. The study will last up to 8 weeks including screening period.
Looking for future studies?
Notify Me18 year–85 year
All sexes
Interventional
Phase 1
Velocity Clinical Research, New Smyrna Beach, Edgewater, Florida, United States
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Administered orally.
Time frame: Predose up to 34 days postdose
PK: AUC0-∞ of LY3473329
Time frame: Predose up to 34 days postdose
PK: AUC0-tlast of LY3473329
Time frame: Predose up to 34 days postdose
PK: Cmax of LY3473329
Eli Lilly and Company
Industry
Pharmacokinetics of LY3473329 Following Oral Administration in Participants With Renal Impairment Compared With Participants With Normal Renal Function
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05936138
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications
Miami, Florida, United States
View Trial DetailsNCT06890208
Anxiety Disorders, Arrhythmias, Cardiac
Hamburg, Germany
View Trial DetailsNCT04876963
Arrhythmias, Cardiac, Cardiovascular Diseases
Copenhagen, Denmark
View Trial DetailsNCT07165015
Chronic Disease, Disease Attributes
Orlando, Florida, United States
View Trial Details